Displaying drugs 8801 - 8825 of 9176 in total
Pimivalimab
Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen).
Investigational
Mibavademab
Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).
Investigational
Nadecnemab
Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).
Investigational
Favezelimab
Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).
Investigational
Apamistamab iodine I-131
Investigational
SB719125
Investigational
Lenadogene nolparvovec
Investigational
Rebisufligene etisparvovec
Investigational
Ranuzifigene civaparvovec
Experimental
Adlinacogene civaparvovec
Adlinacogene civaparvovec is an investigational in vivo genome editing therapeutic product. It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX. Developed by Sangamo Therapeutics Inc., it is being investigated...
Experimental
Devafidugene civaparvovec
Devafidugene civaparvovec is an investigational in vivo genome editing product. It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase (IDUA) enzyme. Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Experimental
Dirloctocogene samoparvovec
Investigational
Cotoretigene toliparvovec
Investigational
Entacingene turiparvovec
Investigational
Fordadistrogene movaparvovec
Investigational
Pariglasgene brecaparvovec
Investigational
Patidistrogene bexoparvovec
Investigational
Domofenogene zalfaparvovec
Domofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.
Experimental
Ifezuntirgene inilparvovec
Experimental
Ixoberogene soroparvovec
Investigational
Zaftuclenegene piruparvovec
Experimental
Human Laminin-111
Investigational
Recombinant methionyl brain-derived neurotrophic factor
Investigational
Tegoprubart
Investigational
ABO-202
Investigational
Displaying drugs 8801 - 8825 of 9176 in total